Uma Sinha
Technik-/Wissenschafts-/F&E-Leiter bei EIDOS THERAPEUTICS, INC.
Vermögen: 81 300 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jonathan Fox | M | 66 | 8 Jahre | |
| Neil Kumar | M | 45 | 9 Jahre | |
| Charles Homcy | M | 75 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 24 Jahre |
| Christine Siu | F | 47 | 11 Jahre | |
| Ali Satvat | M | 46 | 8 Jahre | |
| Eric Aguiar | M | 62 | 6 Jahre | |
| Bruce Culleton | M | 57 | 1 Jahre | |
| Francis McCormick | M | 73 | 9 Jahre | |
| Andrew Lo | M | 63 | 9 Jahre | |
| José Ignacio Jiménez Santos | M | 49 | - | |
| Andrea Ellis | F | 38 | 3 Jahre | |
| Hannah Valantine | M | 72 | 3 Jahre | |
| Brian Stephenson | M | 43 | 6 Jahre | |
| Ronald Daniels | M | 64 | 4 Jahre | |
| Bill Doyle | M | 61 | 2 Jahre | |
| Todd Girolamo | M | 59 | 2 Jahre | |
| Richard Scheller | M | 70 | - | |
| Brian Pereira | M | 65 | 2 Jahre | |
| Fred Hassan | M | 78 | 3 Jahre | |
| Randal Scott | M | 66 | 4 Jahre | |
| John Maraganore | M | 60 | 2 Jahre | |
| Alan Lotvin | M | 62 | 2 Jahre | |
| Jennifer Fox | F | 53 | 2 Jahre | |
| Douglas Dachille | M | 59 | 3 Jahre | |
| Eric Michael David | M | 56 | - | |
| Pablo Legorreta | M | 60 | 2 Jahre | |
| Burns McClellan | M | - | - | |
| Vikram Bali | M | - | - | |
| James Momtazee | M | 52 | 8 Jahre | |
| Joseph Stavas | M | 69 | 5 Jahre | |
| Jennifer Cook | F | 58 | 5 Jahre | |
| James Coulston | M | 48 | 2 Jahre | |
| Adora Ndu | M | 43 | 2 Jahre | |
| Christine Seidman | M | 71 | - | |
| Nikhil Pereira-Kamath | M | - | - | |
| Thomas Trimarchi | M | - | 3 Jahre | |
| Jonathan A. Barr | M | - | 3 Jahre | |
| Darin Weber | M | 56 | 4 Jahre | |
| Jung Choi | F | 54 | 9 Jahre | |
| Matthew Outten | M | 49 | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| William Lis | M | 59 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 18 Jahre |
| John J. Schembri | M | 62 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 4 Jahre |
| James Topper | M | 62 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 7 Jahre |
| Mardi Dier | F | 60 | 14 Jahre | |
| Franco Valle | M | 43 | 3 Jahre | |
| Mark Goldsmith | M | 62 | 2 Jahre | |
| Cameron Turtle | M | 34 | - | |
| Mark Perry | M | 68 | 7 Jahre | |
| Stephen Bardin | M | 34 | 3 Jahre | |
| Ted Love | M | 65 | 9 Jahre | |
| Joshua Lehrer-Graiwer | M | 50 | 7 Jahre | |
| Michael M. Kitt | M | 73 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 12 Jahre |
| Suzanne Hooper | F | 58 | 1 Jahre | |
| Peter Radovich | M | 46 | 6 Jahre | |
| Hing Leung Sham | M | 71 | - | |
| Robert M. Califf | M | 72 | 3 Jahre | |
| Todd J. Lorenz | M | 70 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 7 Jahre |
| Raj Shah | M | 46 | 2 Jahre | |
| John Curnutte | M | 72 | 8 Jahre | |
| Robert Scarborough | M | - | 3 Jahre | |
| R. Lee Douglas | M | 72 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 10 Jahre |
| Jean George | F | 66 | 8 Jahre | |
| Willie Lewis Brown | M | 90 | - | |
| Lewis Williams | M | 74 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 18 Jahre |
| Brenton Saunders | M | 56 | 3 Jahre | |
| Duke Rohlen | M | 56 | 1 Jahre | |
| Peggy Phillips | F | 70 | 7 Jahre | |
| Deval Patrick | M | 67 | 4 Jahre | |
| Jean-Jacques Bienaimé | M | 70 | 4 Jahre | |
| Henry Ward Wolff | M | 75 | 13 Jahre | |
| Hollings Renton | M | 77 | 10 Jahre | |
| Jeet Mahal | M | 52 | 11 Jahre | |
| Matt Krause | M | - | - | |
| Sanjay Lakhotia | M | - | - | |
| Katherine Yau | F | - | 1 Jahre | |
| Ching Yau Yi | F | - | 3 Jahre | |
| Eli M. Wallace | M | 57 | - | |
| Michael Henderson | M | 34 | 6 Jahre | |
| Jennifer A. Troia | F | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 5 Jahre |
| Debanjan Ray | M | 46 | 2 Jahre | |
| Patrick A. Broderick | M | 66 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 3 Jahre |
| Daniel D. Gretler | M | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 7 Jahre |
| Robert Blum | M | 60 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 7 Jahre |
| Mark D. Perrin | M | 67 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 6 Jahre |
| Vaughn M. Kailian | M | 79 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 12 Jahre |
| Janice Castillo | F | - | - | |
| Farah Champsi | F | 62 | 8 Jahre | |
| William Ringo | M | 78 | - | |
| Brian W. Metcalf | M | 78 | - | |
| Peter S. Roddy | M | 64 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 12 Jahre |
| Laura Brege | F | 66 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 8 Jahre |
| Hsiao Lieu | M | 53 | 2 Jahre | |
| Rebecca Sunshine | F | 61 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 6 Jahre |
| Ho Young Huh | M | 54 | - | |
| Lynn M. Hughes | F | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | - |
| Robert J. Terifay | M | 64 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 6 Jahre |
| Thomas Hancock | M | 60 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 5 Jahre |
| Charles de Chasteigner du Mée | M | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 8 Jahre |
| Neil Giese | M | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | - |
| Paul Herzich | M | 46 | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
